NASDAQ:BOLD - Audentes Therapeutics Stock Price, Forecast & News

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

Audentes Therapeutics Inc (NASDAQ:BOLD) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.07. During the same quarter last year, the business posted ($0.97) earnings per share. View Audentes Therapeutics' Earnings History.

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Audentes Therapeutics.

17 equities research analysts have issued 1 year price targets for Audentes Therapeutics' shares. Their forecasts range from $10.00 to $60.00. On average, they expect Audentes Therapeutics' stock price to reach $50.54 in the next year. This suggests that the stock has a possible downside of 15.7%. View Analyst Price Targets for Audentes Therapeutics.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 14 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Audentes Therapeutics.

News headlines about BOLD stock have trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Audentes Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Audentes Therapeutics.

Some companies that are related to Audentes Therapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), BioNTech (BNTX), Qiagen (QGEN), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer LP Unit (ET), Exelixis (EXEL), Global Blood Therapeutics (GBT), Gilead Sciences (GILD), Intel (INTC), bluebird bio (BLUE), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Ionis Pharmaceuticals (IONS) and Myriad Genetics (MYGN).

(BOLD) raised $75 million in an initial public offering (IPO) on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Audentes Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Syquant Capital Sas (1.66%), FNY Investment Advisers LLC (0.60%), Vertex One Asset Management Inc. (0.25%), Mission Wealth Management LP (0.01%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Audentes Therapeutics stock include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics.

BOLD stock was sold by a variety of institutional investors in the last quarter, including Mission Wealth Management LP. Company insiders that have sold Audentes Therapeutics company stock in the last year include Louis G Lange, Matthew R Patterson and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.

BOLD stock was acquired by a variety of institutional investors in the last quarter, including Syquant Capital Sas, FNY Investment Advisers LLC, Vertex One Asset Management Inc. and Nisa Investment Advisors LLC. View Insider Buying and Selling for Audentes Therapeutics.

Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BOLD stock can currently be purchased for approximately $59.97.

Audentes Therapeutics has a market capitalization of $2.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe.View Additional Information About Audentes Therapeutics.

The official website for Audentes Therapeutics is http://www.audentestx.com/.

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]